Ligand Pharmaceuticals
LGNDLigand Pharmaceuticals Incorporated (NASDAQ: LGND) is a biopharmaceutical company based in the United States. Its business model is focused on developing and acquiring royalty-generating pharmaceutical assets and technologies, which it then partners with other companies for further development and commercialization. A core component of this strategy is its proprietary Captisol® technology, a chemically modified cyclodextrin used to improve the solubility, stability, and bioavailability of drug compounds. This platform has been utilized in multiple FDA-approved products. The company’s revenue is primarily derived from royalties and material sales from its partnered programs. Ligand’s portfolio includes interests in therapies across various therapeutic areas, including oncology, osteoporosis, and infectious disease. Notable partnered products utilizing its technologies or from its acquisitions include Promacta® (eltrombopag), Kyprolis® (carfilzomib), and Veklury® (remdesivir). This diversified partner-based approach is designed to provide a revenue stream with reduced direct exposure to the costs and risks of late-stage clinical development and commercialization. As a publicly traded entity, Ligand Pharmaceuticals operates by leveraging its scientific and financial assets to build a broad portfolio of revenue-generating partnerships. The company’s activities are centered on the licensing of its technologies and the strategic acquisition of royalty rights to existing and development-stage drug programs, positioning it as a financier and enabler within the broader biopharmaceutical industry.
LGND · Stock Price
Historical price data
About
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is a biopharmaceutical company based in the United States. Its business model is focused on developing and acquiring royalty-generating pharmaceutical assets and technologies, which it then partners with other companies for further development and commercialization. A core component of this strategy is its proprietary Captisol® technology, a chemically modified cyclodextrin used to improve the solubility, stability, and bioavailability of drug compounds. This platform has been utilized in multiple FDA-approved products. The company’s revenue is primarily derived from royalties and material sales from its partnered programs. Ligand’s portfolio includes interests in therapies across various therapeutic areas, including oncology, osteoporosis, and infectious disease. Notable partnered products utilizing its technologies or from its acquisitions include Promacta® (eltrombopag), Kyprolis® (carfilzomib), and Veklury® (remdesivir). This diversified partner-based approach is designed to provide a revenue stream with reduced direct exposure to the costs and risks of late-stage clinical development and commercialization. As a publicly traded entity, Ligand Pharmaceuticals operates by leveraging its scientific and financial assets to build a broad portfolio of revenue-generating partnerships. The company’s activities are centered on the licensing of its technologies and the strategic acquisition of royalty rights to existing and development-stage drug programs, positioning it as a financier and enabler within the broader biopharmaceutical industry.